GOALI: E. coli Metabolic Engineering to Produce the Marine Anticancer Agent Lomaiviticin A

目标:大肠杆菌代谢工程生产海洋抗癌剂 Lomaiviticin A

基本信息

  • 批准号:
    0932612
  • 负责人:
  • 金额:
    $ 28.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
    Standard Grant
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-01 至 2012-08-31
  • 项目状态:
    已结题

项目摘要

0932612PfeiferIntellectual merit This project originates from a complementary partnership between Tufts University and Wyeth Research. The Wyeth Natural Products Discovery Group is recognized as a leader in industrial natural products-based drug discovery and development and has recently sequenced the gene cluster responsible for a potent anticancer compound called lomaiviticin A. The gene sequence was isolated from the marine bacterium Salinispora pacifica naturally responsible for lomaiviticin A production. Unfortunately, lomaiviticin A production from S. pacifica is time-consuming (7-14 days), inconsistent, and low-yielding (0.5 mg/L). In this project, E. coli will be used as a heterologous host for lomaiviticin A biosynthesis with the logic that E. coli will overcome the current S. pacifica production limitations. Here, the Principal Investigator's (PI's) group at Tufts University will lead efforts to transfer the lomaiviticin A gene cluster to E.coli for subsequent heterologous production. The Tufts team specializes in genetic transfer strategies to facilitate complex natural product production through convenient heterologous hosts. Together, the industrial-academic collaboration is well-suited for the production of this important marine anticancer agent through perhaps the ideal biological host. Broader impactsThe synergistic and complementary academic-industrial partnership between Tufts and Wyeth will promote unique broader impact opportunities. Through Tufts, the project will use research as an educational and outreach mechanism. The research itself crosses numerous disciplines that include: molecular biology, microbiology, chemistry, genetics, and chemical and biological engineering. Students at two educational levels (graduate and undergraduate) will have the opportunity to participate in and learn from this multi-disciplinary approach. In addition, individual research responsibilities have been designed to re-enforce the academic level of the student. The graduate student will oversee and manage the experimental efforts in Aims 1 and 2 while simultaneously guiding undergraduate assistants. Hence, the graduate student will develop as an independent scientist and will also gain mentoring experience as he/she trains younger students. The undergraduate student will learn process culturing and analysis skills that coincide with their chemical and biological engineering curriculum. As part of the outreach initiatives, the undergraduate will be selected from the Tufts NSF-sponsored Computer Science, Engineering, and Mathematics Scholars program that encourages underrepresented groups to pursue science and engineering and for whom the PI serves as an academic advisor. Finally, the students will be able to compare academic and industrial research opportunities and gain first-hand access to both climates through summer internships hosted by Wyeth.
该项目源于塔夫茨大学和惠氏研究公司的互补合作伙伴关系。惠氏天然产物发现小组是公认的工业天然产物药物发现和开发的领导者,最近对一种有效的抗癌化合物lomaiviticin a的基因簇进行了测序,该基因序列是从海洋细菌Salinispora pacifica中分离出来的,该细菌自然负责lomaiviticin a的生产。不幸的是,从太平洋杉中生产洛马维菌素A耗时(7-14天),不稳定,产量低(0.5 mg/L)。在本项目中,大肠杆菌将作为lomaiviticin a生物合成的异源宿主,其逻辑是大肠杆菌将克服目前太平洋葡萄球菌的生产限制。在这里,塔夫茨大学的首席研究员(PI)小组将领导将lomaiviticin A基因簇转移到大肠杆菌中进行后续的异源生产。塔夫茨团队专门研究遗传转移策略,通过方便的异源宿主促进复杂的天然产物生产。总之,这种工业-学术合作非常适合通过理想的生物宿主生产这种重要的海洋抗癌剂。更广泛的影响塔夫茨和惠氏之间的协同和互补的学术-产业伙伴关系将促进独特的更广泛的影响机会。通过塔夫茨大学,该项目将把研究作为一种教育和推广机制。这项研究本身跨越了许多学科,包括:分子生物学、微生物学、化学、遗传学、化学和生物工程。两个教育层次(研究生和本科生)的学生将有机会参与并从这种多学科方法中学习。此外,个人研究责任的设计是为了加强学生的学术水平。研究生将监督和管理目标1和目标2的实验工作,同时指导本科生助理。因此,研究生将发展成为一名独立的科学家,并在他/她培训年轻学生的过程中获得指导经验。本科学生将学习过程培养和分析技能,与他们的化学和生物工程课程相吻合。作为拓展计划的一部分,该本科生将从塔夫茨国家科学基金会(Tufts nsf)赞助的计算机科学、工程和数学学者项目中选出,该项目鼓励未被充分代表的群体攻读科学和工程,PI将为他们担任学术顾问。最后,学生们将能够比较学术和工业研究机会,并通过惠氏主办的夏季实习获得两种气候的第一手资料。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Blaine Pfeifer其他文献

Blaine Pfeifer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Blaine Pfeifer', 18)}}的其他基金

I-Corps: Entrepreneurial Development of a Metal-binding Technology Platform
I-Corps:金属结合技术平台的创业开发
  • 批准号:
    1550378
  • 财政年份:
    2015
  • 资助金额:
    $ 28.68万
  • 项目类别:
    Standard Grant
Collaborative Research: Overproduction and Harvesting of Methylated Triterpenes in a Heterologous Host
合作研究:异源宿主中甲基化三萜的过量生产和收获
  • 批准号:
    1410075
  • 财政年份:
    2014
  • 资助金额:
    $ 28.68万
  • 项目类别:
    Standard Grant
GOALI: E. coli Metabolic Engineering to Produce the Marine Anticancer Agent Lomaiviticin A
目标:大肠杆菌代谢工程生产海洋抗癌剂 Lomaiviticin A
  • 批准号:
    1216288
  • 财政年份:
    2011
  • 资助金额:
    $ 28.68万
  • 项目类别:
    Standard Grant

相似国自然基金

E. coli O157:H7外膜蛋白质通过维持细胞膜稳定性的抗非热杀菌作用机制
  • 批准号:
    LR23C200002
  • 批准年份:
    2023
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
利用E. coli融合表达体系及群体感应系统构建抗肿瘤工程菌株
  • 批准号:
    31700032
  • 批准年份:
    2017
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目
E. maxima Th1细胞因子抑制相关抗原的确定及其抑制作用机制的研究
  • 批准号:
    31672545
  • 批准年份:
    2016
  • 资助金额:
    63.0 万元
  • 项目类别:
    面上项目
格嵌入γ.e.度的研究
  • 批准号:
    19371042
  • 批准年份:
    1993
  • 资助金额:
    2.4 万元
  • 项目类别:
    面上项目

相似海外基金

Defining E. coli Diversity in Complex Samples: Methods for Surveillance & Transmission
定义复杂样品中的大肠杆菌多样性:监测方法
  • 批准号:
    MR/Y034449/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.68万
  • 项目类别:
    Research Grant
Mechanisms underlying diarrhea and gut inflammation mediated by Enterotoxigenic and Enteropathogenic E. coli
产肠毒素和致病性大肠杆菌介导的腹泻和肠道炎症的机制
  • 批准号:
    10674072
  • 财政年份:
    2023
  • 资助金额:
    $ 28.68万
  • 项目类别:
SBIR Phase I: Point-of-Care Diagnostic Tool for Identifying Extended Spectrum β-Lactamase E. Coli in Urinary Tract Infection
SBIR 第一阶段:用于识别尿路感染中的超广谱 β-内酰胺酶大肠杆菌的即时诊断工具
  • 批准号:
    2233653
  • 财政年份:
    2023
  • 资助金额:
    $ 28.68万
  • 项目类别:
    Standard Grant
Utilizing the power of synthetic biology and De Novo design for the overexpression and biochemical stabilization of KCNA6 or Kv1.6 potassium channels in the E. coli expression system
利用合成生物学和 De Novo 设计的力量,实现大肠杆菌表达系统中 KCNA6 或 Kv1.6 钾通道的过度表达和生化稳定
  • 批准号:
    10666856
  • 财政年份:
    2023
  • 资助金额:
    $ 28.68万
  • 项目类别:
Identification of coexistence relationships and phenotypic traits of virulence and resistance genes by large-scale E. coli genome analysis
通过大规模大肠杆菌基因组分析鉴定毒力和抗性基因的共存关系和表型特征
  • 批准号:
    23K07947
  • 财政年份:
    2023
  • 资助金额:
    $ 28.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular Pathogenesis of enterotoxigenic E. coli associated enteropathy
产肠毒素大肠杆菌相关性肠病的分子发病机制
  • 批准号:
    10656056
  • 财政年份:
    2023
  • 资助金额:
    $ 28.68万
  • 项目类别:
Characterization of the RRS: a new chromosomal structural element in E. coli
RRS 的表征:大肠杆菌中的一种新染色体结构元件
  • 批准号:
    10752809
  • 财政年份:
    2023
  • 资助金额:
    $ 28.68万
  • 项目类别:
Examining the mechanisms of epoxytigliane induced biofilm disruption in antibiotic resistant E coli
检查环氧替利亚烷诱导抗生素耐药性大肠杆菌生物膜破坏的机制
  • 批准号:
    BB/Y51276X/1
  • 财政年份:
    2023
  • 资助金额:
    $ 28.68万
  • 项目类别:
    Training Grant
Microfluidic Impedance Biosensor for the Detection of E. coli in Waterways
用于检测水道中大肠杆菌的微流控阻抗生物传感器
  • 批准号:
    2882939
  • 财政年份:
    2023
  • 资助金额:
    $ 28.68万
  • 项目类别:
    Studentship
Defining the physiology of E. coli O157:H7 in cattle to develop phage-based interventions
定义牛体内大肠杆菌 O157:H7 的生理学以开发基于噬菌体的干预措施
  • 批准号:
    BB/X007022/1
  • 财政年份:
    2023
  • 资助金额:
    $ 28.68万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了